Drug Profile
EOS 200271
Alternative Names: EOS200271; PF 06840003Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator iTeos Therapeutics
- Developer iTeos Therapeutics; Ludwig Institute for Cancer Research
- Class Antineoplastics; Indoles; Small molecules; Succinimides
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Glioma
Most Recent Events
- 27 Jan 2020 Discontinued - Phase-I for Glioma (Late-stage disease, Recurrent) in USA (PO) (NCT02764151; Pfizer and iTeos Therapeutics pipeline, January 2020)
- 27 Jan 2020 Discontinued - Preclinical for Cancer in Belgium (unspecified route) (NCT02764151; Pfizer and iTeos Therapeutics pipeline, January 2020)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Glioma(Late-stage disease, Recurrent) in USA (PO)